A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Prolactinoma - females; Adenoma - secreting; Prolactin-secreting adenoma of the pituitary
Not everyone needs treatment for prolactinoma.
Medication is usually successful in treating prolactinoma. Surgery is done in some cases where the tumor may damage vision.
In women, treatment can improve:
Men should be treated when they have:
Large prolactinomas generally must be treated to prevent vision loss.
Bromocriptine and cabergoline are drugs that reduce prolactin levels in both men and women. They usually must be taken for life. If the drug is stopped, the tumor may grow and produce prolactin again, especially if it is a large tumor. Most people respond well to these drugs, although large prolactinomas are more difficult to treat. Both drugs may cause dizziness and upset stomach.
Using bromocriptine over time can reduce the chance of being cured by removing the tumor. Therefore, if surgery is needed, it is best to remove the tumor during the first 6 months of using this drug.
Radiotherapy with conventional radiation or gamma knife is usually reserved for patients with prolactinoma that continues or gets worse after both medication and surgery.
The outlook depends on the success of medical therapy or surgery. Tests to check whether the tumor has returned after treatment are important.
If untreated, a growing tumor can press on the optic nerves and cause:
See your health care provider if you have any symptoms of prolactinoma.
If you have had a prolactinoma in the past, call your health care provider if the symptoms return.
Melmed S, Kleinberg D. Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology. Philadelphia, PA: Saunders Elsevier; 2008:chap 8.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885